Muthoot Microfin Limited has successfully completed the allotment of ₹1,500 crore worth of non-convertible debentures (NCDs) through private placement. The Debenture Issue and Allotment Committee approved this significant capital raising exercise on December 16, 2025, following the Board of Directors' initial approval from their meeting dated May 8, 2025.

NCD Allotment Structure

The company has structured the NCD issuance into two distinct series, each targeting different investor preferences and tenure requirements:

Security and Risk Management

The NCDs are classified as Listed, Rated, Senior, Secured, Transferable, and Redeemable instruments, providing multiple layers of investor protection. The debentures are secured by a first-ranking and exclusive charge of 1.05 times over the company's receivables, including present and future receivables that are free from any encumbrances, charges, or liens.

This security structure ensures that the outstanding principal amount, together with accrued interest, maintains adequate collateral coverage throughout the tenure of the instruments. The receivables-based security model aligns well with Muthoot Microfin's core business operations in the microfinance sector.

Market Listing and Compliance

The NCDs will be listed on BSE Limited, providing liquidity options for investors during the tenure period. The allotment has been conducted in accordance with Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company has confirmed that no delays in payment of interest or principal amount for more than three months from the due date are anticipated, and there are no existing defaults in payment obligations. This clean track record supports the company's creditworthiness in the debt market.

Strategic Implications

This ₹1,500 crore capital infusion represents a substantial funding achievement for Muthoot Microfin, providing the company with resources to expand its microfinance operations and strengthen its market position. The differentiated coupon rates between the two series reflect the term premium, with the longer 36-month Series II offering a higher rate of 9.95% compared to 9.85% for the 24-month Series I.

The monthly coupon payment structure offers regular income streams for investors while supporting the company's cash flow management. This successful private placement demonstrates strong investor confidence in Muthoot Microfin's business model and growth prospects in the competitive microfinance sector.

Achyut Healthcare Limited has received a substantial acquisition disclosure from AKSHIT M. RAYCHAHUF under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure pertains to the acquisition of equity shares through open market transactions completed on December 12, 2025.

Acquisition Details and Shareholding Changes

AKSHIT M. RAYCHAHUF acquired 31,500 equity shares of Achyut Healthcare Limited through open market purchase, representing 0.013% of the company's total share capital. The acquisition increased the acquirer's total shareholding from 1.83% to 1.84% of the company's equity share capital.

Company Share Capital Structure

Achyut Healthcare Limited maintains a total equity share capital of ₹23.56 crores, comprising 2,35,57,000 equity shares of ₹1.00 each. The company's share capital structure remained unchanged before and after the reported acquisition, with the total diluted share capital also standing at the same level.

Regulatory Compliance and Disclosure

The disclosure was made in compliance with SEBI regulations governing substantial acquisition of shares and takeovers. AKSHIT M. RAYCHAHUF confirmed belonging to the promoter group of the target company, making this acquisition part of promoter group shareholding activities. The acquirer holds no encumbered shares, voting rights other than through equity shares, or convertible securities in the company.

Transaction Characteristics

The acquisition represents a routine open market purchase without any special features or conversion rights. The shares acquired are regular equity shares with standard voting rights, and no warrants or convertible securities were involved in this transaction. The disclosure maintains transparency in shareholding changes as mandated by securities market regulations.